Spyre Therapeutics Inc (NAS:SYRE)
$ 35.92 0.79 (2.25%) Market Cap: 1.83 Bil Enterprise Value: 1.63 Bil PE Ratio: 0 PB Ratio: 8.35 GF Score: 51/100

Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 01:20PM GMT
Release Date Price: $197.75 (-1.25%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. The next presenting company is Aeglea. And presenting on behalf of the company, we have CEO, Anthony Quinn. Before I turn it over to Tony, I just wanted to highlight for those on the webcast would like to submit a question, please use the Ask a Question feature and the portal, and I'd be happy to ask the question on your behalf. With that, I'll turn it over to Tony.

Anthony G. Quinn
Aeglea BioTherapeutics, Inc. - President, CEO, Principal Financial Officer & Director

Great. Thanks, Anupam. Thanks for the invitation. So good morning, everybody. I'm very pleased to join you virtually at this year's JPMorgan conference. So at Aeglea, we are thinking differently about the science of human enzymes. We're reimagining the potential of these natural catalysts to benefit people with rare

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot